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Abstract
Background: Hyperalgesia is a well recognized hallmark of disease. Pro-inflammatory cytokines have been
suggested to be mainly responsible, but human data are scarce. Changes in pain threshold during systemic
inflammation evoked by human endotoxemia, were evaluated with three quantitative sensory testing methods.
Methods and Results: Pressure pain thresholds, electrical pain thresholds and tolerance to the cold pressor test
were measured before and 2 hours after the intravenous administration of 2 ng/kg purified E. coli endotoxin in 27
healthy volunteers. Another 20 subjects not exposed to endotoxemia served as controls. Endotoxemia led to a rise in
body temperature and inflammatory symptom scores and a rise in plasma TNF-α, IL-6, IL-10 and IL-1RA. During
endotoxemia, pressure pain thresholds and electrical pain thresholds were reduced with 20±4 % and 13±3 %,
respectively. In controls only a minor decrease in pressure pain thresholds (7±3 %) and no change in electrical pain
thresholds occurred. Endotoxin-treated subjects experienced more pain during the cold pressor test, and fewer
subjects were able to complete the cold pressor test measurement, while in controls the cold pressor test results
were not altered. Peak levels and area under curves of each individual cytokine did not correlate to a change in pain
threshold measured by one of the applied quantitative sensory testing techniques.
Conclusions and Significance: In conclusion, this study shows that systemic inflammation elicited by the
administration of endotoxin to humans, results in lowering of the pain threshold measured by 3 quantitative sensory
testing techniques. The current work provides additional evidence that systemic inflammation is accompanied by
changes in pain perception.
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Introduction
Pain is a major source of suffering in intensive care patients
and commonly involves patients with concurrent inflammatory
conditions like trauma, auto-immune diseases, or infectious
diseases. Highly organized neural circuits existing in the brain
and spinal cord regulate pain. These circuits in turn are
influenced by a number of pathological states, including
inflammation. Inflammation leads to a broad constellation of
adaptive changes, called the ‘sickness response’. Features of
this response include fever, increased sleep, decreased
locomotion, decreased food and water intake, and hormonal
changes [1]. Furthermore, the pain threshold for painful stimuli
is lowered, resulting in hyperalgesia, and normally non-painful
stimuli can become painful (allodynia). Hyperalgesia
constitutes an underexposed clinical problem on the intensive
care, which deserves specific attention, since e.g. opiates that
are frequently used in everyday practice can actually worsen
hyperalgesia [2]. Animal studies have shown that inflammatory
cytokines contribute to the development of hyperalgesia [3-6].
However, data in humans in vivo are scarce.
Quantitative sensory testing (QST) provides a standardized
way of pain threshold quantification, as a result of which it is
increasingly used in clinical and research settings. QST
comprises several techniques to measure the intensity of
stimuli needed to produce specific sensory perceptions.
Common stimuli employed are touch or pressure, vibration,
electrical stimulation or exposure to heat or cold [7].
Intravenous administration of endotoxin in healthy
volunteers, a well-characterized standardized model of
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systemic inflammation, results in an acute systemic
inflammatory response characterized by high cytokine levels
and flu-like symptoms [8]. In the present study, pain thresholds,
measured by three separate methods of QST, were
investigated before and after the administration of 2 ng/kg of E.
Coli endotoxin in healthy volunteers to quantify the difference in
pain perception caused by systemic inflammation. Additionally,
we assessed the relation between circulating levels of
inflammatory cytokines and pain thresholds to gain further
insight in the pathophysiological mechanisms linking
inflammation and pain perception.
Materials and Methods
Design
The study consisted of two parts. In the first part 27 healthy
young males were subjected to experimental human
endotoxemia, during which quantitative sensory testing was
performed before and two hours after endotoxin administration.
In the second part, 20 healthy young males underwent the
same QST measurement regimen without endotoxemia, to
identify any possible carry-over or time-dependent effects
(control experiments). The study was not designed as a
randomized controlled trial, as it was considered unethical to
expose subjects in the control experiments to the risks and
discomfort of the placement of an arterial and venous catheter,
while no fluid was administered and no blood was sampled
from them.
Experimental human endotoxemia
The study was approved by the local ethics committee
Commissie Mensgebonden Onderzoek (CMO) regio Arnhem –
Nijmegen, The Netherlands and the study was conducted
according to the principles expressed in the Declaration of
Helsinki. After written informed consent was obtained, 27
healthy male volunteers participated in the endotoxemia
treated study group, which was part of a larger endotoxemia
Figure 1.  Plasma cytokine levels during human endotoxemia.  Data expressed as mean±SEM. At T=0 h endotoxin was
administered. A: TNF-α, B: IL-10, C: IL-6, D: IL-1RA. h: hours.
doi: 10.1371/journal.pone.0084159.g001
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Figure 2.  Relative change in pain thresholds during human endotoxemia.  A: combined pain pressure threshold (PPT) and B:
combined electrical pain threshold (EPT) measured 2 hours after endotoxin administration. Values are depicted as percentage
change from baseline (-1 h), where baseline was set at 100%. White bars: control subjects, black bars: endotoxin treated subjects.
Data expressed as mean±SEM. h: hours.
doi: 10.1371/journal.pone.0084159.g002
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trial (NCT 01349699). Pre-study screening revealed no
abnormalities in medical history, physical examination, routine
laboratory tests and ECG. At 7:30 AM subjects were admitted
to the research unit of our intensive care department. A
cannula was placed in an antecubital vein to permit the infusion
of 1.5 litre of 2.5%glucose/0.45% saline solution in 1 hour prior
to endotoxin administration, followed by 150 ml/h until 6 h after
endotoxin infusion and 75 ml/h until the end of the experiment
to ensure optimal hydration [9]. A 5-lead ECG and an arterial
catheter in the brachial artery of preferably the non-dominant
arm, enabled continuous monitoring of hemodynamics as well
as the regular drawing of blood for cytokine measurements. At
T=0 h, 2 ng/kg U.S. Reference Escherichia coli endotoxin (E.
coli O:113, Clinical Center Reference Endotoxin, National
Institute of Health, Bethesda, USA) was administered
intravenously over 1 minute. Subjects were asked to rate each
of their inflammatory symptoms (headache, backache, muscle
ache, shivering and nausea) on a 0–5 Likert scale every 30
minutes following endotoxin administration. Also, body
temperature was taken every 30 minutes throughout the
experiment using an automatic infrared tympanic thermometer
(Genius 2, Tyco healthcare group LP, Mansfield, MA, USA).
EDTA anti-coagulated blood for the determination of IL-6, TNF-
α, IL-10 and IL-1RA was drawn one hour before endotoxin
Figure 3.  Change in tolerance to the cold pressor test during human endotoxemia.  A and B: Amount of discomfort in
response to immersion of one hand in ice water, rated on a 0-10 numeric rating scale (NRS). C and D: Percentage of subjects with
hand in ice water. Open circles: .
T=-1 hour (before endotoxin treatment), black dots: T=2 hours, (after endotoxin treatment). A and C: results in endotoxin treated
group, B and D: results in control group.
doi: 10.1371/journal.pone.0084159.g003
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administration, and at t=0, 0.5, 1, 1.5, 2, 3, 4, 6 and 8 hours
afterwards. Blood samples were immediately centrifuged at
2.000 g for 10 minutes at 4°C and supernatants were stored at
–80 °C until batch wise determination of cytokine
concentrations using a simultaneous Luminex assay according
to the manufacturer’s instructions (Bio-plex cytokine assay;
Bio-Rad, Hercules, California, USA).
Quantitative sensory testing
Somatic Pressure Pain Thresholds (PPT) and Electrical Pain
Thresholds (EPT) were determined in dermatome C5, T10 and
L3, one hour before and two hours after LPS administration.
Measurements in dermatome C5 took place at the site of the
greater tubercle of the upper arm, in dermatome T10 at the
location of the iliac crest, and in L3 at the vastus lateralis
muscle, half way the upper leg. All measurements were carried
out contra-laterally to the side where the arterial cannula was
placed. The subjects were asked to indicate thresholds for pain
detection (stimulus just becoming painful), after which the
stimulus was interrupted immediately. Both electrical and
pressure pain thresholds were determined 3 times
consecutively in each dermatome. The instructions given to the
subjects were repeated after every 3 stimuli. All tests were
performed in a highly standardized fashion by 2 members of
our group to minimize interobserver variability. PPT
measurement was performed by gradually increasing pressure
with a pressure algometer (Somedic, Hörby, Sweden) until the
subject indicated to experience the applied pressure as pain by
saying ‘stop’.
Electrical stimuli were administered transcutaneously in a
gradually increasing mode (JNI Biomedical APS, Aalborg,
Denmark) via self-adhesive electrodes. The current was
gradually increased from 0 to 50 milliamperes until the subject
ended the measurement himself by lifting his thumb from a
metal handle at the moment the feeling just started to get
painful, thereby automatically stopping the electric stimulus.
For both PPT and EPT the measurements in different
dermatomes were analysed separately, but to give a more
general estimate of the pain threshold also a mean value of the
three dermatomes was calculated which will be referred to as
‘combined PPT’ and ‘combined EPT’.
The Cold Pressor Test (CPT) was carried out as previously
described [10]. Briefly, one hand of the subject was submerged
to the wrist in water with melting crushed ice (0 °C). From the
start of ice immersion, the subject was asked to rate the pain
severity on a 0-10 Numeric Rating Scale (NRS) every 10
seconds. The subject was free to remove his hand from the ice
water at any time by himself if he could not tolerate the cold
any longer. The measurement was stopped by the
investigators after 90 seconds or if the subject rated the pain
severity as 10. Both the NRS scores as well as the time to
removal of the hand (latency) from the ice water were
analyzed.
Control experiments
To correct for possible time-dependent effects or the
development of tolerance to the pain stimuli, 20 healthy
subjects were subjected to QST measurements without
administration of endotoxin. The protocol and timing of the QST
measurements were identical to the measurements in the
endotoxin-treated subjects, but subjects did not fast 12 hours
before the start of the experiments, did not receive a venous or
arterial cannula, no hydration fluid was administered, and no
blood samples were drawn.
Statistical analysis
For the PPT and EPT, the average of three consecutive
threshold measurements was calculated at each time point.
Students paired T-test was used to compare mean pain
thresholds within subjects. Correlation analysis was performed
using Spearman rank R correlation or Pearson’s R correlation
according to the distribution of the parameters tested
(Spearman rank R for change in pain threshold (i.e. ΔPT = PT
after–PT before) versus cytokine induction, and Pearson’s R for
Correlations between the different QST methods). Differences
in tolerance to the cold pressor test were evaluated with
McNemar’s test for paired comparisons for binominal data,
survival analyses using the Log-rank test and repeated
measures two- way ANOVA (interaction term). Differences in
proportions were analyzed with Fisher’s exact test. Statistical
calculations were performed using Graphpad Prism V5.0
(Graphpad software) and SPSS 18.0 (PASW Statistics). Data
are represented as mean ± SEM, unless otherwise stated.
Because of the anticipated large variation in baseline pain
perception between subjects, data were analyzed as % change
from baseline per subject. Results were considered statistically
significant at P<0.05.
Results
Baseline characteristics
There were no significant differences in demographic
characteristics between the subjects in the endotoxin treated
group (n=27, age 22±0.6 years, BMI 22.8±0.4 kg/m2) and
control subjects (n=20, age 22±0.5 years, BMI 22.2±0.7 kg/m2).
All subjects were of European descent. There was a difference
in baseline pain perception between controls and subjects;
Baseline PPT was significantly higher in the endotoxin-treated
group (Combined PPT 701±49 versus 491±46 N, p=0.004),
while the baseline EPT was similar in both groups (Combined
EPT 15.5±1.4 versus 12.1±1.4 mV, p=0.1). Also, no difference
in baseline tolerance to the cold pressure test was observed,
the % of subjects that could tolerate the ice immersion for the
entire duration of the measurement was 63 % (LPS group) and
50 % (control group), p=0.77.
Experimental human endotoxemia
LPS administration caused a marked inflammatory response
characterized by flu-like symptoms, an increase in body
temperature of 2.0±0.1 °C and a marked rise in circulating
cytokines in all 27 subjects. Symptoms ranging from headache,
nausea, backache, muscle ache and shivering first occurred
around 1 hour after endotoxin administration and peaked at
T=90 minutes. Thereafter symptoms gradually declined and at
discharge (T=9 h after endotoxin administration) all subjects
Systemic Inflammation Decreases Pain Threshold
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had fully recovered. Peak levels were detected for TNF-α at 1.5
h and IL-6 at 2 h, measuring 580±47 pg/ml and 1286±114
pg/ml, respectively, while IL-10 (435±67 pg/ml) and IL-1RA
(6063±282 pg/ml) peaked at 3 h (Figure 1A-D).
Quantitative sensory testing
Pain thresholds were tested 1 hour before and 2 hours after
LPS administration (Figure 2A-B, Table 1). In the endotoxin
treated group a significant decrease in PPTs was noted at
T=2h for each dermatome separately (C5: -20±5 %, T10: -15±5
%, L3: -23±4 %) as well as for the combined PPT (-20±4 %). In
control subjects, a statistically significant, but less pronounced
reduction in PPT at T=2 h was observed in dermatome C5
(-17±4 %) and combined PPT (-7±3 %).
Electrical pain thresholds were significantly decreased in the
endotoxin treated group (C5: -8±7 %, T10: -14±4 %, L3: -16±3
%, Combined: -13±3 %), but no significant changes were
observed in control subjects.
Subjective pain perception measured by NRS scores in
response to the cold pressor test was highly reproducible
(Figure 3A-B) showing identical curves for the measurements
at t=-1 and T=2 h in control subjects. Two hours after endotoxin
administration, significantly more pain was reported during the
cold pressor test (p<0.0001). Also, the period that subjects
could withstand the exposure to cold was significantly
decreased after endotoxin administration, only 26 % of the
subjects completed the 90 second duration of the
measurement during endotoxemia compared to 63% at T=-1 h
(Figure 3C). The mean time to withdrawal from the ice was
76±4 seconds before endotoxin treatment and 54±5 seconds
after (Figure 3D, p=0.0001). In control subjects there was no
difference between the two measurements (55 % fulfilled the
measurement at T=-1 hr versus 50 % at T=2 h, p=1.00). Mean
time to withdrawal was 77±4 seconds at T=-1 and 75±4
seconds at T=2 h, p=0.51).
Correlation analyses
There was a good correlation between pain threshold
determinations on different dermatomes and a modest, though
statistically significant correlation between pain thresholds
measured by PPT and EPT (Combined PPT vs Combined
EPT: r=0.43, p<0.0001). Correlation analyses revealed no
significant correlations between cytokine levels and changes in
PPT or EPT (Table 2), except for weak correlations of peak
IL-10 and delta PPT C5, IL-10 at T=2 h and delta PPT C5 and
IL-6 at T=2 h and delta CPT. All these correlations lost
significance following Bonferroni’s correction for multiple
testing. Apart from the absence of clinically relevant
correlations between cytokines and differences in pain
thresholds, also no correlations between total symptom score
or separate symptom scores (headache, backache, muscle
ache, shivering and nausea) and changes in EPT, PPT or
tolerance to CPT were found (data not shown).
Discussion
This study reports a clear change in pain perception during
human experimental endotoxemia, and supports previous
findings that suggest a close interrelation between the immune
response and hyperalgesia. A profound difference in pain
perception was found 2 hours after endotoxin administration
which was not found in a group of subjects that did not receive
endotoxin. Although human endotoxemia is a well–validated,
standardized model of inflammation suitable to find possible
correlations between cytokine release and altered pain
thresholds, no such direct correlations were found.
It has been long recognized that substances released by
immune cells can modulate pain perception. The modulation of
pain perception is part of the brain-mediated sickness response
that enhances host survival. Pro-inflammatory cytokines are
thought to initiate this response as they are the key mediators
of immune to brain communication [11,12]. These cytokines
can be produced locally at the site of tissue injury, leading to a
local change in pain threshold. However, in the case of
systemic inflammation, cytokines can induce a generalized
change in pain perception. These cytokines act on signal
transduction at the peripheral nerve terminals, along the nerve
bundles, within the spinal cord and within the brain. In addition
Table 1. Pain thresholds at T=-1 and T=2.
 Endotoxemia (N=27)  No endotoxemia (N=20)
 T=-1 hr T=2 h Delta P-value  T=-1 hr T=2 h Delta P-value
PPT (N)          
C5 636±45 501±44 -136±37 0.001  483±52 402±48 -81±22 0.002
T10 639±50 534±48 -105±34 0.005  433±40 430±46 -3±14 0.85
L3 828±68 612±51 -216±43 <0.0001  556±53 545±62 -11±30 0.72
Combined 701±49 549±45 -152±27 <0.0001  491±46 459±49 -31±14 0.03
EPT (mAmp)          
C5 15.5±1.7 12.9±1.4 -2.6±1.2 0.046  12.8±1.3 12.1±1.4 -0.7±0.7 0.31
T10 17.7±1.9 14.6±1.4 -3.1±0.9 0.002  11.8±1.6 11.7±1.7 -0.1±1.4 0.94
L3 13.3±1.2 11.0±1.1 -2.3±0.6 0.0004  11.8±1.6 11.9±1.7 0.1±0.6 0.86
Combined 15.5±1.4 12.9±1.2 -2.6±0.7 0.0004  12.1±1.4 11.9±1.5 -0.2±0.7 0.75
PPT: Pressure Pain Threshold. EPT: Electrical Pain Threshold. N: newton. mAmp: milliamperes
doi: 10.1371/journal.pone.0084159.t001
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they can activate the vagus nerve which is also involved in pain
perception and the sickness response [13].
IL-1 is regarded as the most important and potent cytokine in
modulation of pain perception. Hyperalgesia can (at least in
part) be blocked by anti-IL-1 directed therapies, while other
pro-inflammatory cytokines such as TNF-alpha, and IL-6 are
thought to influence pain perception mainly through IL-1
induction, illustrated by the fact that hyperalgesia caused by
pro-inflammatory cytokines other than IL-1 is attenuated by
blocking IL-1 signalling [14,15]. In contrast with the
hyperalgesic effects of pro-inflammatory cytokines, the anti-
inflammatory cytokine IL-1 receptor antagonist (IL-1RA) and
IL-10 have shown to increase pain thresholds when
administered intrathecally [16-19]. Not only systemic production
of IL-1 is associated with hyperalgesia, also de novo production
and release of IL-1 in the brain and the dorsal ganglia of the
spinal cord are involved in sickness-induced hyperalgesia [20].
In addition, nerve growth factor (NGF) may represent a final
common pathway, as NGF is synergistically induced by both
IL-1 and TNF- alpha [21,22]. As IL-1 plays a pivotal role in
changes of pain perception, it appears logical to measure IL-1
production in the current study as well. However, during human
endotoxemia plasma IL-1 is not or only marginally elevated
[23]. In contrast, IL-1RA, the natural inhibitor of IL-1, is
markedly elevated after endotoxin administration, suggesting
that there is a significant induction of IL-1 within the tissues,
which is not reflected in the circulation, but which could
modulate pain perception. This may be a explanation for the
fact that no correlation between changes in pain thresholds and
measured circulating cytokines was found. An alternative
explanation is that the effects of bacterial-derived inflammatory
stimuli on pain perception are not mediated by inflammatory
cytokines but by these bacterial products themselves, as
hyperalgesia in mice was recently shown to be dependent on
bacterial load rather than immune activation [24]. In agreement,
bacterial products, including LPS, can directly activate
nociceptor neurons [24,25].
Systemic inflammation has previously been shown to alter
pain perception in animals and humans. Recently, Benson and
colleagues reported altered pain perception after the
administration of a very low dose of endotoxin (0.4 ng/kg) to
healthy volunteers, mimicking low grade systemic inflammation
[26]. The current work provides additional evidence that
systemic inflammation is accompanied by changes in pain
perception. However, in contrast to the study of Benson et al.
[26] no correlations were found between plasma levels of
cytokines and changes in pain perception. A possible
explanation might be that Benson et al. [26] used a 5 times
lower dose of endotoxin, only inducing a mild inflammatory
reaction. Furthermore, the reported correlations are difficult to
Table 2. Spearman correlations of changes in pain thresholds and cytokines.
  TNF-α  IL-6  IL-10  IL-1RA
  Peak Value at t=2 h  Peak Value at t=2 h  Peak Value at t=2 h  Peak Value at t=2 h
ΔPPT (N)           
C5 r 0.187 0.013  -0.062 -0.111  0.455 * 0.412 *  0.064 0.100
 P-value 0.342 0.949  0.755 0.575  0.015 0.029  0.746 0.614
T10 r 0.017 -0.059  0.164 0.102  -0.034 -0.092  -0.299 0.002
 P-value 0.932 0.767  0.404 0.606  0.864 0.641  0.122 0.993
L3 r -0.083 -0.167  0.121 0.144  0.030 0.067  0.050 -0.044
 P-value 0.674 0.394  0.540 0.465  0.879 0.736  0.799 0.823
Combined r 0.155 0.056  0.200 0.173  0.223 0.164  0.026 0.093
 P-value 0.430 0.776  0.308 0.379  0.255 0.404  0.894 0.638
ΔEPT (mAmp)            
C5 r 0.218 0.131  -0.003 -0.129  -0.045 -0.094  -0.286 -0.265
 P-value 0.275 0.516  0.988 0.522  0.825 0.641  0.148 0.181
T10 r -0.128 0.052  0.053 -0.020  -0.181 -0.184  -0.009 -0.380
 P-value 0.525 0.797  0.792 0.919  0.365 0.357  0.965 0.051
L3 r 0.194 0.170  -0.022 -0.119  0.009 -0.089  -0.093 -0.245
 P-value 0.333 0.398  0.914 0.554  0.963 0.660  0.646 0.219
Combined r 0.194 0.170  -0.022 -0.119  0.009 -0.089  -0.093 -0.245
 P-value 0.333 0.398  0.914 0.554  0.963 0.660  0.646 0.219
ΔCPT (NRS)           
 r -0.038 -0.063  0.293 0.415 *  0.102 0.166  0.249 0.248
 P-value 0.848 0.749  0.130 0.028  0.606 0.399  0.201 0.203
Δ: Delta. Pressure Pain Threshold. EPT: Electrical Pain Threshold. CPT: Cold Pressor Test. NRS: Numeric Rating Scale. N: Newton. mAmp: milliamperes. *:p<0.05
doi: 10.1371/journal.pone.0084159.t002
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interpret: similarly to the present study, no correlations between
changes in pain thresholds and peak or area under curve
cytokine levels were found. The only significant correlations
were found at time points either before or after peak levels of
the respective cytokines. This implies that a type-1 error may
have occurred, as no correction for multiple testing was
performed. Based on their and our observations, we suggest
that cytokines may lower the pain threshold, but that this effect
is likely modulated by one or more other downstream
mechanisms. A possible mechanism could be the regulation of
pain by glia cells of the CNS [27]. In addition, activation of the
vagus nerve by other substances apart from cytokines [13] as
well as local production of IL-1 in peripheral tissues and the
central nervous system may play an important role.
A limitation to the study is that the group not treated with
endotoxin did not receive a venous and arterial catheter, did
not receive (pre)hydration solution and did not fast 12 hours
before the start of the experiments. Possibly one of these
factors resulted in the baseline differences as were found in
PPT and EPT. Because paired observations within the same
subject were obtained, data were analyzed as change from
baseline per subject, and no direct statistical comparisons
between the endotoxemia group and non-endotoxemia were
made, this should have no influence on the interpretation of the
study results. Strong aspects of the present study are the fact
that we used a validated, standardized model of systemic
inflammation, in which purified endotoxin elicited a pronounced
inflammatory response, reflected by high levels of circulating
cytokines, even compared with septic patients [8]. Furthermore,
time-dependent bias was excluded by the inclusion of a non-
endotoxin treated study group. Also, three different domains of
QST measurements were used; electrical stimulation, pressure
algometry, and cold pressor testing, providing solid evidence
that multiple measures of somatic pain perception are altered
by systemic inflammation.
The findings of this and previous studies, indicating a clear
relation between inflammation and pain perception, contribute
to our understanding of pain in systemically inflamed patients
such as those suffering from sepsis. Furthermore this study
shows that experimental human endotoxemia offers a valuable
model to study inflammation-induced hyperalgesia that may
facilitate development of new therapies aimed at modulating
inflammation-related pain perception.
Conclusions
In conclusion, this study shows that systemic inflammation
elicited by the administration of endotoxin to human results in a
decreased pressure pain threshold, a decreased electrical pain
threshold and decreased tolerance to the cold pressor test. In
the absence of a correlation with circulating cytokines, the
nature of the link between inflammation and pain sensation
needs further study.
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